2026-05-19T01:27:28Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/235442024-11-28T16:09:51Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16938col_20.500.12105_16962col_20.500.12105_16967
Repisalud author Perez de Llano, Luis Alejandro author Dacal Rivas, David author Marina Malanda, Nuria author Plaza Moral, Vicente author Gullon Blanco, Jose Antonio author Muñoz-Esquerre, Mariana author Garcia-Moguel, Ismael author Diaz Campos, Rocio M author Martinez-Moragon, Eva author Harbenau Mena, Alicia author García-Cosío, Borja author Padilla Galo, Alicia author Cisneros Serrano, Carolina 2024-10-04T13:58:02Z 2024-10-04T13:58:02Z 2022 De Llano LP, Rivas DD, Malanda NM, Moral VP, Blanco JAG, Munoz-Esquerre M, et al. The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome. J Asthma Allergy. 2022;15:363-9. 10.2147/JAA.S338467 1178-6965 Journal of Asthma and Allergy https://hdl.handle.net/20.500.13003/19867 35330786 L2016373077 2-s2.0-85128300570 https://hdl.handle.net/20.500.12105/23544 773456700001 Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months. Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with ≥1 exacerbation and ≥1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT ≥ 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients. eng Asthma Asthma-COPD overlap COPD The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome research article